Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML
This article was originally published in The Pink Sheet Daily
Executive SummaryNovartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.
You may also be interested in...
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.